The impact and collateral damage of COVID-19 on prostate MRI and guided biopsy operations: Society of Abdominal Radiology Prostate Cancer Disease-Focused Panel survey analysis

Prostate MRI and image Quality: It is time to take stock

Multiparametric magnetic resonance imaging (mpMRI) plays a vital role in prostate cancer diagnosis and management. With the increase in use of mpMRI, obtaining the best possible quality images has become a priority. The Prostate Imaging Reporting and Data System (PI-RADS) was introduced to standardize and optimize patient preparation, scanning techniques, and interpretation. However, the quality of the MRI sequences depends not only on the hardware/software and scanning parameters, but also on patient-related factors. Common patient-related factors include bowel peristalsis, rectal distension, and patient motion. There is currently no consensus regarding the best approaches to address these issues and improve the quality of mpMRI. New evidence has been accrued since the release of PI-RADS, and this review aims to explore the key strategies which aim to improve prostate MRI quality, such as imaging techniques, patient preparation methods, the new Prostate Imaging Quality (PI-QUAL) criteria, and artificial intelligence on prostate MRI quality.

Imaging and physician visits at cancer diagnosis: COVID -19 pandemic impact on cancer care

BACKGROUND

Little is known about the COVID-19 pandemic impact on the provision of diagnostic imaging and physician visits at cancer diagnosis.

METHODS

We used administrative databases from Ontario, Canada, to identify MRI/CT/ultrasound scans and in-person/virtual physician visits conducted with cancer patients within 91 days around the date of diagnosis in 2016-2020. In separate segmented regression procedures, we assessed the trends in weekly volume of these services per thousand cancer patients in prepandemic (June 26, 2016 to March 14, 2020), the change in mean volume at the start of the pandemic, and the additional change in weekly volume during the pandemic (March 15, 2020, to September 26, 2020).

RESULTS

Totally, 403,561 cancer patients were included. On March 15, 2020 (COVID-19 arrived), mean scan volume decreased by 12.3% (95% CI: 6.4%-17.9%) where ultrasound decreased the most by 31.8% (95% CI: 23.9%-37.0%). Afterward, the volume of all scans increased further by 1.6% per week (95% CI: 1.3%-2.0%), where ultrasound increased the fastest by 2.4% (95% CI: 1.8%-2.9%). Mean in-person visits dropped by 47.4% when COVID-19 started (95% CI: 41.6%-52.6%) while virtual visits rose by 55.15-fold (95% CI: 4927%-6173%). In the pandemic (until September 26, 2020), in-person visits increased each week by 2.6% (95% CI: 2.0%-3.2%), but no change was observed for virtual visits (p -value = 0.10).

CONCLUSIONS

Provision of diagnostic imaging and virtual visits at cancer diagnosis has been increasing since the start of COVID-19 and has exceeded prepandemic utilization levels. Future work should monitor the impact of these shifts on quality of delivered care.